Feasibility of a tapering opioids prescription program for trauma patients at high risk of chronic consumption (TOPP-trauma): protocol for a pilot randomized controlled trial

M. Bérubé 1,2*, V. Deslauriers 3, S. Leduc 3,4, V. Turcotte 4, S. Dupuis 4,5, I. Roy 4, S. Clairoux 4,5, S. Panic 3,4 and M. Nolet 4,6

Abstract

Background: Opioid use disorder (OUD) and deaths related to the chronic use of opioids have increased significantly over the last two decades. Chronic consumption of opioids has been documented in many patients with traumatic injuries. Preliminary research findings have shown that interventions using cognitive-behavioral strategies were a promising adjunct in decreasing the burden associated with opioid consumption. Accordingly, the Tapering Opioids Prescription Program in Trauma (TOPP-Trauma) was developed.

Purpose: To assess the feasibility of the TOPP-Trauma intervention and its research methods; and explore the potential efficacy of TOPP-Trauma in reducing opioid consumption.

Methods: A 2-arm pilot randomized controlled trial (RCT) will be conducted in patients presenting a high risk for chronic opioid consumption. Fifty participants at high risk for chronic consumption of opioid will receive either TOPP-Trauma or an educational pamphlet. The feasibility assessment of TOPP-Trauma will be based on the ability to provide its components as initially planned. Several parameters will be evaluated to determine the feasibility of the research methods, including the adequacy of the sampling pool, the dropout rate, and the ease of data collection. The morphine equivalent dose (MED) per day between both groups will be measured at 6 and 12 weeks. Pain intensity and pain interference with activities will also be evaluated at the same time points.

Discussion: This study will provide evidence on the feasibility of a preventive program aimed at reducing chronic opioid use in high risk trauma patients. Information will also be gathered on the methods that should be used to test the efficacy of such programs.

Trial registration: International Standard Randomized Controlled Trial Number (ISRCTN): 40263056. Registered 26 May 2018.

Keywords: Analgesics, opioid, Opioid-related disorders, Risk factors, Secondary prevention, wound and injuries, Self-care, Cognitive therapies, Feasibility studies, Pilot projects

* Correspondence: melanie.berube@fsi.ulaval.ca

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The Growing Social Concern Associated with Chronic Opioid Consumption In recent years, there has been an alarming rise in chronic opioid consumption that has led to increased morbidity and mortality. The increase in opioid prescriptions, which tripled over the last decade, was identified as one of the most significant factors related to this opioid crisis [1]. Chronic opioid consumption is defined as an opioid usage persisting beyond 12 weeks [2]. Opioid consumption that exceeds this period of time will result in patients more likely to require chronic therapy for years [3] and affects up to 35% of trauma patients [4].

Chronic consumption of opioids was shown to increase the odds of opioid-use disorder (OUD), including opioid dependence, abuse, or overdose, by 15 to 122 times, depending on the dose prescribed [5]. Postsurgically, the total duration of opioid use was the strongest predictor of OUD, with each additional week of opioid use increasing the rate of OUD by 44% [6]. Similarly, between 2007 and 2017, the hospitalization rate due to opioid intoxication increased by 53% [7]. Moreover, in the United States, overdose deaths, excluding those related to fentanyl, have increased by 185% (from 6158 to 17,536 deaths) over the past 15 years [8]. In Canada, there were close to 4000 opioid-related deaths in 2017 [9]. Even more alarming, opioid-related overdoses are now one of the main causes of death for the 18-35 year old age group in the United States and Canada [10, 11].

Risk Factors Linked to Chronic Opioid Consumption
The risk factors of chronic opioid use in trauma patients include: pre-injury use of opioids or substance abuse [2, 12–14], low socioeconomic status [13, 15], high Injury Severity Score (ISS) [15], psychological vulnerability (i.e., depression, anxiety, pain catastrophizing) [2, 16], and low pain self-efficacy (i.e., a person’s confidence in her/ his ability to manage pain and perform activities while in pain) [4]. Interventions to prevent the chronic consumption of opioids among patients presenting these risk factors are therefore warranted.

Interventions to Prevent Chronic Opioid Consumption
Secondary to the undertreatment of pain observed at the beginning of this century, the American Pain Society [17] and the Joint Comission [18] identified pain assessment as the fifth vital sign. Consequently, the widespread use of opioids became the norm, including in postoperative pain management [19]. However, until recently, opioid prescribers minimized the risks of OUD [20]. Hence, patients were, and are still, often discharged from the hospital without adequate education and follow-up [20, 21].

Fortunately, interventions using educational, cognitive (i.e., alteration of maladaptive thoughts and emotions, problem-solving) and behavioral strategies (i.e., staying active, relaxation skills, returning to preferred activities) [22] have yielded promising results. For example, a retrospective surgeon-controlled cohort study, testing the effect of preoperative counseling (i.e., providing education and advice) on the duration of postoperative opioid use in orthopedic trauma, showed that patients with counseling were significantly more likely to cease opioids by six weeks than those without [23]. However, the effect was not sustained at 12 weeks. Furthermore, a practice-based study assessing the outcomes of an acceptance and commitment therapy (ACT), which uses cognitive-behavioral strategies [24], revealed that patients who received ACT after major surgery, for reasons other than a traumatic injury, showed significantly less opioid use, pain interference with activities, and depressed mood, up to five months post-surgery [25].

Similarly, a retrospective study on patients with chronic spine pain found that those who received a combination of interventional (including exercise and physical therapy) and cognitive motivational counseling on analgesic medication used significantly less opioids at 6 months, than those who received interventional therapies only [26]. Cognitive motivational counseling aims to help patients rely on other pain self-management strategies, rather than on medication alone. The efficacy of such a treatment package was also underscored in a recent systematic scoping review on gastrointestinal disorders, which concluded that the greatest reductions in opioid misuse were observed when the promotion of self-management behaviors and drug monitoring with audit and feedback were used [27].

Based on positive preliminary findings associated with interventions aimed at reducing opioid consumption, we developed the Tapering Opioids Prescription Program for Trauma Patients at High Risk for Chronic Consumption (TOPP-Trauma). This program was adapted from a self-management intervention designed to prevent the acute to chronic pain transition in patients with major lower extremity trauma (iPACT-E-Trauma) [28–30]. This intervention focuses on the various dimensions of pain, pharmacological and non-pharmacological (i.e., cryotherapy, limb elevation, relaxation exercises) strategies for acute pain management, health promotion strategies, and a return to pre-injury activities. The activities included in the intervention are similar to those found in interventions based on the cognitive-behavioral approach – that is, education, problem-solving, graded activity, continued monitoring, and matching of learned self-management behaviors with real-life situations [28, 29].

iPACT-E-Trauma underwent preliminary testing in a trauma population at low risk for the chronic
consumption of opioids (e.g., no pre-injury use of opioids or substance abuse, low ISS, no psychological vulnerability) [31]. Clinicians and patients gave a positive assessment of this intervention’s acceptability [28]. Furthermore, iPACT-E-Trauma was deemed feasible, [30] with achievable research methods [31].

In addition to the content and activities from iPACT-E-Trauma for the self-management of acute pain, TOPP-Trauma will integrate education about opioid misuse and patient monitoring, for those presenting risk factors for chronic opioid consumption after a traumatic injury. Before progressing to a full scale RCT, this study aims to determine the capacity to provide the components specific to TOPP-Trauma, and whether the research methods can measure the potential effects of this intervention on opioid consumption in particular.

Methods
Aims
The objectives of this study are to:

1) Evaluate the feasibility of TOPP-Trauma (i.e., the ability to deliver the intervention as planned and of participants to complete pre-established activities) [32].
2) Evaluate the feasibility of the research methods (i.e., the adequacy, effectiveness, and efficiency of the study protocol in gathering pertinent data from participants, that is representative of the target population and that will address the objectives preset for the intervention) [32] to test TOPP-Trauma.
3) Describe the potential efficacy of TOPP-Trauma in reducing the chronic consumption of opioid.

Design
The design selected is a two-arm pilot randomized controlled trial, to mirror the elements that would be present in a future full-scale RCT [33]. Particularly, in terms of randomization acceptance to either the experimental or control group for patients with traumatic injuries with a high risk profile for chronic consumption, and the attrition rate in both groups at the end of the study. Two groups will be studied concurrently and followed at the different study time points (T1 to T8) presented in Fig. 1. In addition to standard pain management treatments, the control group will receive an educational pamphlet, while the experimental group will receive the same pamphlet accompanied by a structured follow-up with the TOPP-Trauma research team.

Setting
The study will be conducted in a level-1 trauma center in Montreal, Canada, admitting 1400 trauma patients, on average, annually. Ethics committee approval was obtained from the Centre Intégré Universitaire de Santé et de Services Sociaux du Nord-de-l’Île-de-Montréal Research Ethics Board (REB) (project identification number: 2019–1621).

Eligibility Criteria
The inclusion criteria will be: 1) having suffered a traumatic injury (e.g., fractures to the extremity and the spine, thoraco-abdominal injuries), 2) at least 18 years of age, 3) able to read and speak French or English, 4) ≥ 2 doses/day of opioids during the three previous days, 5) at least one risk factor for chronic consumption, and 6) discharged directly from hospital to home. The risk factors for chronic consumption are: a) annual income ≤ $40,000 [13, 15], b) ISS ≥ 12 [15], c) pre-injury use of opioid or substance abuse [Alcohol, Smoking and Substance Involvement Screening Test – version 3.0 ≥ 11 for alcohol and ≥ 4 for other substances [2, 12–14, 34], d) anxiety or depression symptoms [scores ≥11 on the Hospital Anxiety and Depression Scale [2, 16, 35]; e) pain catastrophizing [score ≥ 20 on the Pain Catastrophizing Scale [2, 16, 36], and f) pain self-efficacy [score < 17 on the Pain Self-Efficacy Questionnaire [4, 37]. The exclusion criterion will be patients with cognitive impairment [i.e., moderate-severe traumatic brain injury (TBI) – Glasgow Coma Scale score < 13/15 [38], dementia and severe psychiatric disorder] affecting the capacity to participate in the study.

Intervention
Control group
Participants randomized to the control group will receive the standard pain management intervention, consisting in non-opioid analgesics and opioids to control pain, as well as an educational pamphlet. The pamphlet will be provided to participants by the interventionist before hospital discharge, with no specific guided sessions, reflecting what is most commonly implemented in clinical practice. Furthermore, we hope to determine if patients receiving only an educational pamphlet are more likely to drop out than patients with follow-up. We also wish to explore if education at hospital discharge is sufficient to reduce long-term consumption of this type of analgesic.

Experimental group
Participants in the experimental group will receive TOPP-Trauma as well as the standard pain management intervention. The biopsychological model of pain [39], empirical data from previously tested opioid tapering interventions, the iPACT-E-Trauma intervention [28–30], and clinical knowledge on the trauma patient population guided the development of TOPP-Trauma.
Program Content

The biopsychosocial model of pain [39] emphasizes that disorders, such as pain, result from the dynamic interaction between biological, psychological, and social factors which may perpetuate and worsen pain. This model was influenced by the neuromatrix theory of pain [40, 41]. According to this theory, pain is the consequence of an output from a widely distributed brain neural network, impacting the biological and psychological dimensions of pain. The social dimension (e.g., daily living activities, environmental stressors) can trigger additional biopsychological reactions, thus contributing to the vicious circle of nociception, increased pain intensity, distress, and disability [42]. Hence, the biopsychosocial model of pain highlights the need to address pain management with multimodal strategies, in order to foster minimal opioid use.

TOPP-Trauma will focus on the same self-management behaviors promoted in iPACT-E-Trauma. In addition, counseling on opioid tapering and the use of alternative pain management strategies, as well as continued monitoring of opioid intake, will be provided. Recommendations on opioid tapering will be based on the adequacy of pain relief (pain intensity < 4/10 and pain mildly or not
interferring with daily living activities). A dose reduction of 25% per day will be suggested at each session, until opioid cessation or until patients chronically prescribed opioids reach their target maintenance dose, as per guidelines on acute pain management [43].

Program structure
TPOP-Trauma combines two 10-minute educational sessions within the week prior to hospital discharge, and a maximum of six 15-minute opioid tapering counseling sessions every two weeks following discharge (Table 1). A trauma case manager nurse, a nurse practitioner student or the trauma service pharmacist, who have more than five years of experience in caring for the trauma population along the acute continuum of care will provide the counseling sessions. These clinicians will receive a 4-hour training session by the principal investigator on the conceptual underpinnings of the program, the tools used in the study, and on how to deliver the program through role-play. Moreover, meetings will be held every two weeks between the PI and clinicians who will provide TPOP-Trauma until 10 patients will be recruited and until they will have provided the entire program in at least two patients.

The TPOP-Trauma educational session will be based on the information included in the pamphlet given to the control group. Counseling sessions will be initiated one week after hospital discharge, and will be discontinued when patients cease opioid use or when the maximum number of planned sessions has been reached. A Program Feasibility Evaluation Logbook will guide session delivery for the trauma nurse and the trauma pharmacist. The treating surgeon will be informed of the opioid tapering plan at the time of the participants’ appointment at the outpatient clinic, to ensure treatment consistency. The number (i.e., dose) and frequency of counseling sessions was determined based on the established timeline for transitioning towards chronic opioid consumption (i.e., 12 weeks) [2] and interventions tested in other high-risk populations. These reported a significant decrease in opioid consumption after five to six sessions [25, 26]. Considering that trauma patients admitted in the trauma center where the study will be conducted come from various regions, counseling sessions will either be provided over the phone or face-to-face at the outpatient clinic, at the time of the follow-up appointment with the treating surgeon. Counseling sessions will be delivered at the outpatient clinic whenever possible in order to concomitantly inform the treating surgeons on the opioid tapering plan.

Variables and Measurement Tools
A number of variables will be measured at different time points (Table 2) to screen patients presenting risk factor(s) for chronic opioid consumption and to meet study objectives based on the Statement for Defining Standard Protocol Items for Clinical Trials (SPIRIT) [44]. All the instruments that will be used in this study have shown adequate psychometric properties in French and English (Additional file 1) [34, 45–55]. Moreover, instruments were translated into French using a forward-backward method and/or cultural adaptation.

Sociodemographic and clinical data
A sociodemographic questionnaire will be used to collect data on the age, sex, education, annual income, and ethnic background of participants. An Injury Profile Form will describe injury-related aspects that may affect pain intensity and recovery, including: mechanisms of injury, injuries and their grade, ISS [56], types of treatment received (surgical and nonsurgical), and number of surgeries required.

Screening tools
Data on annual income will be collected through the sociodemographic questionnaire. The Trauma Registry archivists will calculate the ISS within 48 h of patient recruitment or when all the diagnostic tests to identify injuries have been performed. Various instruments will be used to screen for other risk factors for chronic opioid consumption.

Alcohol, smoking and substance involvement screening test (ASSIST) – version 3.0
The ASSIST was developed by the World Health Organization (WHO) and an international group of addiction researchers and clinicians in response to the overwhelming public health burden associated with psychoactive substance use [57]. The ASSIST – version 3.0 is an 8-item questionnaire to screen patients at risk for substance abuse [34]. It gathers information from patients about lifetime substance use and substance use and associated problems over the last 3 months. Patients scoring between 4 and 26 (11 and 26 for alcohol) are at moderate risk of health and other problems related to substance abuse, while a score of 27 and higher suggests that they are at high risk [34].

Hospital anxiety and depression scale (HADS)
The HADS is a 14-item inventory divided into two subscales, each comprising 7 items, to assess anxiety (HADS-A) and depression (HADS-D) [35]. The range of each subscale is 0–21. Cut-off scores for both subscales indicate that 0–7 = normal, 8–10 = mild anxiety/depression, 11–14 = moderate anxiety/depression, and 15–21 = severe anxiety/depression [35].
Pain catastrophizing scale (PCS) The PCS comprises 13 items divided into three subscales (rumination, magnification, and helplessness) measuring catastrophizing thoughts [36]. Total PCS scores range from 0 to 52; a score of 20 represents a moderate to high risk for the development of chronicity [56].

Pain self-efficacy questionnaire (PSEQ) The PSEQ is a 10-item questionnaire to assess a person’s confidence in their ability to manage pain and perform activities while in pain [37]. PSEQ scores range from 0 to 49; scores < 17 represent a low score preventing the modification and maintenance of behavioral change [37].

Feasibility and acceptability
A Program Feasibility Evaluation Logbook will make it possible to collect program feasibility data (Table 3) [58]. The Program Feasibility Evaluation Logbook will detail information on the program components that need to be delivered in each session, the pain self-management strategies applied by participants between sessions, the appropriateness of the physical environment in which

### Table 1 TOPP-Trauma Sessions

| Sessions     | Timing of Delivery | Components                                                                                                                                 |
|--------------|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| Educational - 1 | The week prior to hospital discharge | - The various components of pain (introduction to the biopsychosocial dimensions of pain and how they negatively or positively influence pain experience)  
- How to assess pain intensity  
- Adequate use of analgesics prescribed  
- Need to taper opioids to prevent abuse and dependence  
- How to use cryotherapy |
| Educational - 2 | The week prior to hospital discharge | - How to use deep breathing relaxation exercises  
- The need to stay active  
- How to establish objectives for staying active with the SMART procedure (establish an objective with the participant)  
- The influence of sleep hygiene on pain and the characteristics of an adequate sleep hygiene  
- The strategies to achieve adequate sleep hygiene |
| Counseling - 1 | One week after hospital discharge | - Assessment of patient’s average pain intensity at rest and upon movement in the last 48 h  
- Follow up on activity objective  
- Assessment of analgesics taken over the last 72 h.  
- Assessment of non-pharmacological pain management strategies used over the last 72 h and underscoring the importance of using these strategies  
- Providing information on how to gradually reduce the consumption of analgesics (e.g., 25% opioid dose reduction OR decrease frequency of opioid use, e.g., every 6 h instead of every 3–4 h OR before activities causing high-intensity pain) if pain < 4/10 and does not interfere with activities  
- Assisting the participant to establish an objective for staying active according to the SMART procedure to be met in 2 weeks. |
| Counseling - 2 | Two weeks after counseling session 1 | - Same as counseling sessions 1 and 2.  
- Providing information on how to gradually reduce the consumption of analgesics (i.e., no need to take opioids on a regular basis unless specified by her/his physician; to rely principally on acetaminophen to manage their pain and to use opioids only in the presence of pain interfering with activities not relieved by other strategies).  
- Encouraging the patient to consult her/his physician and providing a list of support resources for substance abuse if still taking opioids at counseling session 6. |
| Counseling - 3 | Two weeks after counseling session 2 | - Same as counseling sessions 1 to 3.  
- Providing information on how to gradually reduce the consumption of analgesics (i.e., no need to take opioids on a regular basis unless specified by her/his physician; to rely principally on acetaminophen to manage their pain and to use opioids only in the presence of pain interfering with activities not relieved by other strategies).  
- Encouraging the patient to consult her/his physician and providing a list of support resources for substance abuse if still taking opioids at counseling session 6. |
| Counseling - 4, 5 and 6 | Two weeks after counseling session 3, 4, 5 | - Same as counseling sessions 1 to 3.  
- Providing information on how to gradually reduce the consumption of analgesics (i.e., no need to take opioids on a regular basis unless specified by her/his physician; to rely principally on acetaminophen to manage their pain and to use opioids only in the presence of pain interfering with activities not relieved by other strategies).  
- Encouraging the patient to consult her/his physician and providing a list of support resources for substance abuse if still taking opioids at counseling session 6. |

**SMART:** specific, measurable, attainable, relevant, time based

---

**Bérubé et al. Pilot and Feasibility Studies (2019) 5:67**

Page 6 of 12
the program is delivered, the time dedicated to adequately deliver the program and answer patient questions, and the challenges faced when providing the program.

Gathering data on the intervention components provided and on challenges in the application of the intervention activities, in the selected mode, and the selected dose, will also demonstrate the fidelity with which the intervention can be delivered [32].

A Research Methods Feasibility Form will assess methodological research criteria parameters, established according to recognized guidelines [32, 58, 59] and data from iPACT-E-Trauma’s preliminary testing [29, 31] (Table 3). This form will monitor: (1) adequacy of the sampling pool and recruitment time, (2) ease with which participants are screened, (3) possibility of applying randomization procedures as planned, (4) attrition rate in experimental and control groups, and (5) ease of data collection (Table 2).

The Treatment Acceptability and Preference (TAP) Questionnaire [59] will be used to evaluate intervention feasibility after its completion. The TAP includes four attributes (i.e., perceived effectiveness, appropriateness, suitability, and convenience) assessed on a 5-point descriptive scale. Patients will be invited to rate intervention’s features based on these attributes. An open-ended questions was added at the end of the questionnaire to gather input on the modifications required to improve intervention acceptability. Reliability, construct validity and discriminant validity of the TAP Questionnaire have been established with a population receiving self-management intervention [60]. The intervention uptake (i.e., the implementation of self-management behaviors and the reduction of opioids as recommended), the enrollment rate, with the reasons for refusing to participate, and the attrition rate, with the reasons for dropping out, will be used to further determine TOPP-Trauma acceptability [32] for patients at high-risk of chronic opioid consumption.

### Variables and Measurement Tools

**Morphine equivalent dose/day**

Opioids taken by participants will be measured by calculating the total morphine equivalent dose (MED) per 24 h, as recommended for studies on the consumption of opioids, using the appropriate conversion methods [61, 62]. Participants will be asked to self-report their opioid use for the last three days and the day associated with the highest MED will be retained. The MED/day will be

---

**Table 2 Schedule of enrollment, intervention and assessments**

| Study time points | Enrollment | Allocation | Post-allocation | Closeout |
|------------------|------------|------------|----------------|----------|
| Participants timeline | -t1 | 0 | t1 t2 t3 t4 t5 | t6 t7 t8 t9 t10 |
| In trauma center | | | t5 | 6 weeks |

| Enrollment: | | | |
| -- | | | |
| Eligibility screen/Informed consent | √ | | |
| Screening - risk factors for chronic consumption of opioids | | | |
| - Sociodemographic questionnaire | √ | | |
| - ISS | √ | | |
| - ASSIST | √ | | |
| - HADS | √ | | |
| - PCS | √ | | |
| - PSEQ | √ | | |

| Allocation of participants | | | | |
| -- | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| Intervention encounters: | | | | |
| -- | | | | |
| Control group | | | | |
| Intervention group | | | | |
| | | | | |
| Assessments: | | | | |
| -- | | | | |
| - Intervention feasibility | | | | |
| - Research methods feasibility | | | | |
| - Acceptability | | | | |
| - MED/day, non-opioid analgesic(s) intake, BPI | | | | |

*S1 to S8: Program sessions 1 to 8*

ISS Injury Severity Score, ASSIST Alcohol, Smoking and Substance Involvement Screening Test; HADS Hospital Anxiety and Depression Scale, PCS Pain Catastrophizing Scale, PSEQ Pain Self-Efficacy Questionnaire, MED Morphine Equivalent Dose, BPI Brief Pain Inventory
measured at 6 weeks after the beginning of TOPP-Trauma, since some studies found that a great proportion of trauma patients do not use opioids beyond this period of time [22], as well as at 12 weeks after initiating the intervention. The medical file will be consulted to determine the highest MED over three days before participant randomization, as part of baseline assessment. A pharmacist, blinded to patient allocation, will compute the MED per day.

Opioid delivery by the community pharmacy
A registry will be used to document the quantity of opioids prepared by the community pharmacy at 6 and 12 weeks after initiating TOPP-Trauma. Community pharmacies will be contacted to gather information on opioids delivered following participant informed consent.

Co-analgesia
Non-opioid analgesics will be measured by asking participants to self-report, at the various follow-up time points, on whether they used ≥2 doses of each class of analgesic, for at least one day over the last three days. The medical record will be reviewed to document the consumption of non-opioid analgesics for the 3 days before randomization. Data on non-opioid analgesics delivered by community pharmacies will also be collected at 6 and 12 weeks after beginning TOPP-Trauma.

Pain and function
The Brief Pain Inventory (BPI) will be used to assess pain intensity and patient function. The BPI includes 11 items: 4 on pain intensity (now, average, worst, least) measured on a 0–10 NRS (0 = no pain; 10 = worst possible pain), and 7 on pain interference with daily living activities, assessed on a 0–10 NRS (0 = does not interfere; 10 = interferes completely) [63]. The BPI item “walking” was replaced by “mobility (ability to get around)” [55] because many trauma patients may be limited in their walking capacity. Moreover, three additional items (pain interference with self-care, recreational

---

### Table 3 Variables to assess the feasibility of the intervention and the research methods

| Variables | Indicators |
|-----------|------------|
| **Intervention feasibility** | | |
| 1- The possibility to deliver the intervention as planned | - Provision of ≥80% of planned components of each in-presence session and of the overall intervention [59]. |
| 2- Participants adhering to the intervention | - Session duration (sessions 1 to 6: 15 min). |
| | - Challenges faced during session delivery. |
| | - Attendance to ≥80% of sessions by participants [59]. |
| | - Involvement in intervention activities and implementation of recommended self-management ≥80% behaviors by participants [59]. |
| **Research methods feasibility** | | |
| 1- Adequacy of the sampling pool and recruitment time | - Obtaining consent from ≥80% of patients approached to participate in the study. |
| 2- Ease of screening | - Percentage of eligible patients who were included in the study. |
| 3- The possibility of applying randomization procedures as planned | - Patient’s reasons for refusal to participate in the study. |
| 4- Attrition rate in experimental and control groups | - Difficulties in obtaining patients’ consent. |
| 5- Ease of data collection procedures | - Recruiting study sample (i.e., 50 participants) in ≤9 months [31]. |
| | - The time required to screen participants relative to recruitment. |
| | - The time required to obtain consent and baseline data relative to recruitment. |
| | - Eligibility criteria not limiting the pool of participants by ≥50% [32]. |
| | - Reasons for ineligibility. |
| | - Difficulties when applying the randomization procedures. |
| | - Patient acceptance to randomization, either to the treatment or control group ≥80% of the time [32]. |
| | - Attrition rate in experimental and control groups, i.e., ≤ 20% [60]. |
| | - Percentage of questionnaires completed in full. |
| | - Pattern and rates of non-answered questions at each time measure. |
| | - Mean time required to complete the outcome questionnaires. |
| | - Mean time period between expected dates for questionnaire completion and actual completion. |
| | - Recall rates (telephone calls or emails) for questionnaire completion. |
activities, and social activities), proposed in a modified version of the BPI [55], will be added to the Pain Interference with Daily Living Activities Subscale to obtain a broader-based sample of areas that could potentially be affected by pain. The worst pain intensity upon movement, on average in the last 7 days, and the worst score for pain interference with daily living activities during the same period, will be measured at 6 and 12 weeks. Baseline measures of pain intensity and interference will cover the previous 48 h.

Sample Size
The pilot study was not designed for adequate statistical power but to test the feasibility and potential efficacy of the program [44]. To reach these aims, we estimate that a total of 50 participants should be randomized into each group (experimental and control). This sample size is realistic considering the number of trauma patients admitted in the center where the study will be conducted.

Recruitment
Research assistants (RA) will identify potential participants and explain the study. If patients meet the inclusion criteria and wish to participate, after receiving detailed information on what the study entails, the RA will obtain their written informed consent. A RA will then administer the screening tools to determine the presence of risk factors for chronic opioid consumption. Only patients with pre-established risk factors will be included in the study.

Allocation
Randomization
The randomization sequence will be generated by a coordinating center, located within the hospital’s research center where the study will be conducted, to keep researchers blinded to allocation. A computerized random-number generator will produce the sequence (i.e., Research Randomizer). Tickets will be placed in sealed, opaque, sequentially numbered envelopes to randomize study participants to either the control or experimental group. Participants will be randomized after collecting baseline data.

Blinding
The expert trauma nurse and the pharmacist who will administer the program will not be blinded to group assignment. To ensure participant blinding to group assignment, the TOPP-Trauma educational session and the educational pamphlet will be given to participants in an office, in private hospital rooms, or in hospital rooms with no other trauma patients present. The RA who will collect and enter the data will be blinded to group assignment. A numerical code will be assigned to each participant, in both groups, to ensure statistician blinding.

Data Collection
Procedure
At enrollment, RAs will complete the Injury Profile Form and Research Methods Feasibility Form. They will also document opioid and non-opioid consumption over the last 3 days and distribute the BPI. During program delivery, the trauma nurse and the pharmacist will record information on the feasibility of the program and the attrition rate via the Program Feasibility Evaluation Logbook and the Research Methods Feasibility Data Form. A RA will contact participants in the experimental and control groups over the phone, or meet them at the outpatient clinic, to document their opioid and non-opioid consumption and complete the BPI questionnaire, at 6 and 12 weeks after randomization. They will also contact participants’ community pharmacies to obtain information on opioid and non-opioid delivery at both time periods.

Data analysis
Feasibility and acceptability
To determine the feasibility of TOPP-Trauma, the rates of program components actually delivered to participants, the challenges faced during program delivery and the pain self-management strategies applied by participants will be calculated. Moreover, mean time required for the delivery of TOPP-Trauma sessions will be computed.

Regarding the Feasibility of Research Methods, the following descriptive data will be obtained: 1) the number of patients screened to participate in the study, of eligible patients, and of participants included, 2) the number of inclusion and exclusion criteria that were not met, 3) the mean time required to obtain consent, to screen participants for their chronic consumption risk, and to obtain baseline data, 3) the percentage of participants who accept to be randomized to either the experimental or control group, 4) the dropout rate relative to each program session and outcome measure time point, 5) the mean time between expected dates for questionnaire completion and actual completion, and 6) the recall rates for questionnaire completion [54].

Mean scores will be calculated with regard to data collected with the TAP Questionnaire. Answers to open-ended questions, pertaining to the modifications required to improve intervention acceptability, will be grouped into categories according to core themes identified during content analysis.
Potential efficacy of the program
All outcome data will be analyzed via an intent-to-treat approach. Mean values will be calculated to determine the direction and amplitude of the differences within and between groups on the outcome measures over time. The percentage of opioid-free participants, of participants taking ≥2 doses per day of each class of non-opioid analgesic, and of participants with mild pain intensity and pain interference with activities (i.e., < 4 of a 0–10 Numerical Rating Scale) [64] will be computed. Data will be analyzed at baseline, 6 weeks and 12 weeks.

Ethical Considerations
Procedures will be implemented to ensure that the information participants provide for this study will remain confidential. All participants will be assigned unique code numbers. Consent forms will be stored separately from the data. A master list, matching the names of participants with their study identification numbers, will be kept in a locked filing cabinet separate from the data. No names or other identifying information will appear in any data that is generated. Study findings will be presented in a comprehensive form and not linked to specific participants. All hard copies of the data will be stored in a locked filing cabinet in a locked office and electronic data will be kept in a computer secured with a password. Data will be stored for 10 years and then destroyed and treated as confidential waste or deleted from the research computer.

Protocol amendments will be communicated to the REB. Finally, the program is not known to be associated with any adverse events. However, if such events should occur during the study they will be documented.

Discussion
Study contributions
Chronic opioid consumption has been identified in a significant number of trauma patients. To this day, no intervention with an adequate research design has been tested to provide high-level evidence-based guidance on how to address this issue. This pilot RCT will provide the required data on the feasibility and acceptability of TOPP Trauma in order to adjust the various features of this intervention before evaluating its effects. Moreover, findings will provide information on the research methods to evaluate the effect of TOPP-Trauma, while providing an adequate estimation of within and between group differences regarding the chronic consumption of opioids, setting the stage for a full RCT. Such research projects could provide trauma teams with scientific direction on how to support patients self-manage their pain while transitioning back into the community, and reduce the social burden associated with the long-term use of opioids.

Study limitations
There is a potential social desirability bias to this study since participants will self-report their opioid use at 6 and 12 weeks. The opioid delivery records provided by the community pharmacy, close to both follow-up time points, should help counter this, validating the participants’ assertions. This procedure will also make it possible to document the total quantity of opioids taken by participants, from hospital discharge to 6 weeks after the beginning of TOPP-Trauma, and from 6 weeks to 12 weeks.

The use of an educational pamphlet only for the control group is another limitation to consider. Indeed, experimental group participants could be more inclined to reduce their consumption of opioids because of the attention they will receive from clinicians and not the intervention per se. Despite the fact that preventing the chronic opioid consumption in high risk trauma patients likely require coaching from qualified health professionals, this limitation will be acknowledged in the interpretation of findings on TOPP-Trauma potential effect. Likewise, we will plan to use a three-arm full-scale efficacy trial to account for the attention received while testing TOPP-Trauma impacts.

Finally, participants from both groups will have to answer numerous questionnaires over a 12-week period, which could induce a participation burden. Moreover, the experimental group will have to attend several program sessions. To avoid drop out and loss to follow-up, participants will complete their sessions and questionnaires at the outpatient surgical clinic while waiting to meet their surgeon, whenever possible.

Additional file

Additional file 1: Psychometric properties of the French and English versions of measurement instruments. (DOC 37 kb)

Abbreviations
ACT: acceptance and commitment therapy; ACT: acceptance and commitment therapy; ASSIST: Alcohol, Smoking and Substance Involvement Screening Test; BPI: Brief Pain Inventory; HADS: Hospital Anxiety and Depression Scale; ISS: Injury Severity Score; MED: morphine equivalent dose; OUD: Opioid use disorder; PCS: Pain Catastrophizing Scale; PSEQ: Pain Self-Efficacy Questionnaire; RA: Research assistants; RCT: randomized controlled trial; REB: Research Ethics Board; TBI: traumatic brain injury; TOPP-Trauma: Tapering Opioids Prescription Program for Trauma; WHO: World Health Organization

Funding
The authors received a grant from the Trauma Association of Canada (no reference number was provided).

Availability of data and materials
Not applicable.

Authors’ contributions
MB and VD designed the proposal and drafted the manuscript. SL, VT, SD, IR, SC, SP and MN provided clinical and methodological advice regarding the research proposal and critically revised the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate

Granted by the Centre Intégré Universitaire de Santé et de Services Sociaux du Nord-de-l’Île-de-Montréal Research Ethics Board (REB) (project identification number: 2019–1621).

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Faculty of Nursing, Laval University, 1050 Avenue de la Médecine, Quebec City, QC, G1V 0A6, Canada. 2Research Center, CHU de Quebec, Quebec City, QC, Canada. 3Department of Surgery, Faculty of Medicine, Université de Montréal, Montréal, QC, Canada. 4Centre Intégré Universitaire de Santé et de Services Sociaux du Nord-de-l’Île-de-Montréal, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada. 5Faculty of Pharmacy, Université de Montréal, Montréal, QC, Canada. 6Department of Anesthesiology, Faculty of Medicine, Université de Montréal, Montréal, QC, Canada.

Received: 17 October 2018 Accepted: 9 April 2019

Published online: 10 May 2019

References

1. Canadian Institute for Health Information. Pan-Canadian Trends in the Prescribing of Opioids, 2012 to 2016. https://secure.cihi.ca/free_products/pan-canadian-trends-opioid-prescribing-2017-en-webp.pdf. Accessed 3 Apr 2018.
2. Callinan CE, Neuman MD, Lacy K, et al. The initiation of chronic opioids: a survey of chronic pain patients. J Pain. 2017;18:360–5.
3. Mantle BC, Fan MY, Eduard MJ, et al. Long-term chronic opioid therapy discontinuation rates from the TROUP study. J Gen Intern Med. 2011;26:1490–7.
4. Rosenblom BN, McCartney CJL, Canzian S, et al. Predictors of prescription opioid use 4 months after traumatic musculoskeletal injury and corrective surgery: a prospective study. J Pain. 2017;18:956–63.
5. Eldlund MJ, Martin BC, Russo JE, et al. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic non-cancer pain: the role of opioid prescription. Clin J Pain. 2014;30:557–64.
6. Brat GA, Agniel D, Bean A, et al. Postsurgical prescriptions for opioid naïve patients and association with overdose and misuse: retrospective cohort study. BMJ. 2018;360:k790.
7. Canadian Institute for Health Information. Opioid-Related Harms in Canada. 2017. https://secure.cihi.ca/free_products/opioid-harms-chart-book-en.pdf. Accessed 3 Apr 2018.
8. National Center on Health Statistics, CDC Wonder. National Oversed Deaths from Selected Prescription and Illicit Drugs 2018 https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates. Accessed 15 Feb 2018.
9. Special Advisory Committee on the Epidemic of Opioid Overdoses. National report: Apparent opioid-related deaths in Canada (January 2016 to September 2017). https://www.canada.ca/en/public-health/services/publications/healthy-living/national-report-apparent-opioid-related-deaths-released-june-2018.html. Accessed 20 Feb 2019.
10. Gomes T, Mamdani MM, Dhallia IA, et al. The burden of premature opioid-related mortality. Addiction. 2014;109:1482–8.
11. Park H, Bloch M. How the epidemic of drug overdose deaths ripples across America. New York Times; 2016.
12. Field CA, Cochran G, Caetron R, et al. Postdischarge nonmedical use of prescription opioids in at-risk drinkers admitted to urban level 1 trauma centers. J Trauma Acute Care Surg. 2014;76:833–9.
13. Gangavalli A, Malge A, Terres G, et al. Misuse of opioids in Orthopaedic postoperative patients. J Orthopa Trauma. 2016;31:e103–9.
14. Holman JE, Stoddard GJ, Higgins TF, et al. Rates of prescription opiate use before and after injury in patients with Orthopaedic trauma and the risk factors for prolonged opiate use. J Bone Joint Surg Am. 2013;95:1075–80.
15. Chaudhary MA, Scully R, Jiang W, et al. Patterns of use and factors associated with early discontinuation of opioids following major trauma. Am J Surg. 2017;214:792–7.
39. Gatchel RJ. Comorbidity of chronic pain and mental health disorders: the biopsychosocial perspective. Am Psychol. 2004;59:795–805.
40. Melzack R. Pain and the neuroumtrix in the brain. J Dent Educ. 2001;65:1378–82.
41. Melzack R. Evolution of the neuroumtrix theory of pain. The Pritnhiu raj lecture: presented at the third world congress of world Institute of Pain, Barcelona 2004. Pain Pract. 2005;5:85–94.
42. Gatchel RJ, Peng YB, Peters ML, et al. The biopsychosocial approach to chronic pain: scientific advances and future directions. Psychol Bull. 2007;133:581–624.
43. Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of Postoperative Pain: a clinical practice guideline from the American pain society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' committee on regional anesthesia, executive committee, and administrative council. J Pain. 2016;17:131–57.
44. Chan A-W, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200–7.
45. Khan R, Chatton A, Nallet A, et al. Validation of the French version of the alcohol, smoking and substance involvement screening test (ASSIST). Eur Addict Res. 2011;17:190–7.
46. Humeniuk R, Ali R, Babor TF, et al. Validation of the alcohol, smoking and substance involvement screening test (ASSIST). Addiction. 2008;103:1039–47.
47. Savard J, Laberge B, Gauthier XG, et al. Evaluating anxiety and depression in HIV-infected patients. J Pers Assess. 1998;71:349–67.
48. Roberge P, Doré I, Menea M, et al. A psychometric evaluation of the French Canadian version of the hospital anxiety and depression scale in a large primary care population. J Affect Disord. 2013;147:171–9.
49. Bjelland I, Dahl AA, Haug TT, et al. The validity of the hospital anxiety and depression scale: An updated literature review. J Psychosom Res. 2002;52:69–77.
50. French DJ, Noël M, Vigneau F, et al. L'Échelle de dramatisation face à la douleur PCS-CF: Adaptation canadienne en langue française de l'échelle Pain Catastrophizing Scale. Can J Behav Sci. 2005;37:181–92.
51. Sullivan M, Bishop S, Pivik J. The pain catastrophizing scale: development and validation. Psychol Assess. 1995;7:524–32.
52. Aguerre C, Bridou M, Le Gall A, et al. Analyse Prélminaire des Qualités Psychométriques de la Version Française du Questionnaire D'Auto-Efficacité envers la Douleur. Douleurs. 2012;13:A94.
53. Serlin RC, Mendoza TR, Nakamura Y, et al. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995;61:277–84.
54. Poundja J, Fikretoglu D, Guay S, et al. Validation of the French version of the brief pain inventory in Canadian veteran suffering from traumatic stress. J Pain Symptom Manag. 2007;33:720–6.
55. Tyler EJ, Jensen MP, Engel JM, et al. The reliability and validity of pain interference measures in persons with cerebral palsy. Arch Phys Med Rehabil. 2002;83:236–9.
56. Baker SP, O'Neil B, Haddon W, et al. The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma. 1974;14:187–96.
57. WHO ASSIST Working Group. The alcohol, smoking and substance involvement screening test (ASSIST): development, reliability and feasibility. Addiction. 2002;97:1183–94.
58. Perepletchikova F, Kazdin AE. Treatment integrity and therapeutic change: issues and research recommendations. Clin Psychol Sci Pract. 2005;12:865–83.
59. Politi D, Hungler B. Nursing research: principles and methods. Philadelphia: Lippincott; 1995.
60. Sidani S, Epstein DR, Bootzin RR, et al. Assessment of preferences for treatment: validation of a measure. Res Nurs Health. 2009;32:419–31.
61. Svendsen K, Bochgrevink PC, Fredheim G, et al. Choosing the unit of measurement counts: the use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses. Palliat Med. 2011;25:725–32.
62. Gilson AM, Maurer MA, Ryan KM, et al. Using a morphine equivalence metric to quantify opioid consumption: examining the capacity to provide effective treatment of debilitating pain at the global, regional, and country levels. J Pain Symptom Manag. 2013;45:681–700.
63. Cleeland CS. The brief pain inventory user guide. The University of Texas, M. D. Anderson Cancer Center; 2009.
64. Gerbershagen HJ, Rothaug J, Kalkman CJ, et al. Determination of moderate-to-severe postoperative pain on the numeric rating scale: a cut-off point analysis applying four different methods. Br J Anaesth. 2011;107:619–26.